Canaccord analyst Edward Nash raised the firm’s price target on Verona Pharma (VRNA) to $106 from $72 and keeps a Buy rating on the shares. The firm said during the quarter, Ohtuvayre product sales revenue was $71.3M, and beat their expectation of $47M, as well as the consensus of $53.1M. 1Q25 was the second full quarter of Ohtuvayre’s launch, and sales revenue showed a 95% sequential growth. Canaccord is encouraged by this result, and believes Ohtuvayre will continue to see fast growth in sales revenue for the rest of the year and beyond.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRNA:
- Verona Pharma’s Strong Market Performance and Strategic Advancements Justify Buy Rating and Increased Price Target
- Verona Pharma price target raised to $85 from $75 at H.C. Wainwright
- Verona Pharma Reports Strong Q1 2025 Earnings
- Verona Pharma’s Earnings Call: O2VERE’s Success Fuels Optimism
- Verona Pharma reports Q1 EPS (2c), consensus (3c)